Clinical breast cancer

publication venue for

A Rare Case of S310F Somatic ERBB2 Mutation in a HER2-Nonamplified Breast Cancer. 2016
Dermatologic Adverse Events Associated With Use of Adjuvant Lapatinib in Combination With Paclitaxel and Trastuzumab for HER2-Positive Breast Cancer: A Case Series Analysis. 2015
Sarcoidosis presenting as metastatic lymphadenopathy in breast cancer. 2014
Antitumor response of an ERBB2 amplified inflammatory breast carcinoma with EGFR mutation to the EGFR-TKI erlotinib. 2013
Morphea as a consequence of accelerated partial breast irradiation. 2011
Long-term clinical response in leptomeningeal metastases from breast cancer treated with capecitabine monotherapy: a case report. 2006
Active Surveillance of Atypical Ductal Hyperplasia of the Breast. 2023
Fertility Preferences and Practices Among Young Women With Breast Cancer: Germline Genetic Carriers Versus Noncarriers.. 23. 2022
A Phase II Single-arm Study of Palbociclib in Patients With HER2-positive Breast Cancer With Brain Metastases and Analysis of ctDNA in Patients With Active Brain Metastases.. 23. 2022
Primary and Secondary Breast Sarcoma: Clinical and Pathological Characteristics, Prognostic Factors, and Nomograms for Predicting Survival.. 22. 2022
Adjuvant Radiation Therapy for T3N0 Breast Cancer Patients Older Than 75 Years After Mastectomy: A SEER Analysis.. 18. 2018
Hot Spot and Whole-Tumor Enumeration of CD8⁺ Tumor-Infiltrating Lymphocytes Utilizing Digital Image Analysis Is Prognostic in Triple-Negative Breast Cancer.. 18. 2018
Phase 2 Study of Dose-Dense Doxorubicin and Cyclophosphamide Followed by Eribulin Mesylate With or Without Prophylactic Growth Factor for Adjuvant Treatment of Early-Stage Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.. 18. 2018
Phase II Study of Paclitaxel and Dasatinib in Metastatic Breast Cancer.. 18. 2018
Omission of Adjuvant Radiotherapy in the Elderly Breast Cancer Patient: Missed Opportunity?. 18. 2018
Characteristics and Prognostic Factors for Patients With HER2-overexpressing Breast Cancer and Brain Metastases in the Era of HER2-targeted Therapy: An Argument for Earlier Detection.. 18. 2017
Expanding Implementation of ACOSOG Z0011 in Surgeon Practice.. 18. 2017
The State of Surgical Axillary Management and Adjuvant Radiotherapy for Early-stage Invasive Breast Cancer in the Modern Era.. 18. 2017
Phase I Trial of Veliparib, a Poly ADP Ribose Polymerase Inhibitor, Plus Metronomic Cyclophosphamide in Metastatic HER2-negative Breast Cancer.. 18. 2017
Folate Receptor Alpha Expression Is Associated With Increased Risk of Recurrence in Triple-negative Breast Cancer.. 17. 2017
Can Sentinel Lymph Node Biopsy Be Spared in Papillary Carcinoma of the Breast?. 17. 2016
Characteristics and Outcomes of Patients With Breast Cancer With Leptomeningeal Metastasis.. 17. 2016
Excellent Long-term Breast Preservation Rate After Accelerated Partial Breast Irradiation Using a Balloon Device.. 16. 2016
Hyperactivated mTOR and JAK2/STAT3 Pathways: Molecular Drivers and Potential Therapeutic Targets of Inflammatory and Invasive Ductal Breast Cancers After Neoadjuvant Chemotherapy.. 16. 2015
Biomarkers That Predict Sensitivity to Heat Shock Protein 90 Inhibitors.. 16. 2015
A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer.. 16. 2015
Higher Stage of Disease Is Associated With Bilateral Mastectomy Among Patients With Breast Cancer: A Population-Based Survey.. 16. 2015
Equivalent Survival With Mastectomy or Breast-conserving Surgery Plus Radiation in Young Women Aged < 40 Years With Early-Stage Breast Cancer: A National Registry-based Stage-by-Stage Comparison.. 15. 2015
Efficacy of Scalp Cooling in Preventing Chemotherapy-Induced Alopecia in Breast Cancer Patients Receiving Adjuvant Docetaxel and Cyclophosphamide Chemotherapy.. 15. 2015
Disease-free survival according to the use of postmastectomy radiation therapy after neoadjuvant chemotherapy.. 15. 2014
Second cancer, breast cancer, and cardiac mortality in stage T1aN0 breast cancer patients with or without external beam radiation therapy: a national registry study.. 15. 2014
Inflammatory breast cancer management in the national comprehensive cancer network: the disease, recurrence pattern, and outcome.. 15. 2014
Association between ligands and receptors related to the progression of early breast cancer in tumor epithelial and stromal cells.. 15. 2014
A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer.. 14. 2013
Impact of oncotype DX recurrence score in the management of breast cancer cases.. 14. 2013
Is there a tradeoff in using modified high tangent field radiation for treating an undissected node-positive axilla?. 14. 2013
A comparison of epidemiology, biology, and prognosis of inflammatory breast cancer in Japanese and US populations.. 13. 2013
Randomized phase II trial of weekly vs. every 2 weeks vs. every 3 weeks nanoparticle albumin-bound paclitaxel with bevacizumab as first-line chemotherapy for metastatic breast cancer.. 13. 2013
Prognostic markers for invasive micropapillary carcinoma of the breast: a population-based analysis.. 13. 2013
Relationship between lymphocytopenia and circulating tumor cells as prognostic factors for overall survival in metastatic breast cancer.. 12. 2012
Isolated sternal involvement in breast cancer: is it truly stage IV disease?. 11. 2011
Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer.. 11. 2011
Dose dense cyclophosphamide, methotrexate, fluorouracil is feasible at 14-day intervals: a pilot study of every-14-day dosing as adjuvant therapy for breast cancer.. 10. 2010
Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer.. 10. 2010
Clinical outcomes of patients with breast cancer in a phase I clinic: the M. D. Anderson cancer center experience.. 10. 2010
Intravenous bisphosphonate therapy does not acutely alter nuclear bone scan results.. 10. 2010
Hepatitis C virus infection does not preclude standard breast cancer-directed therapy.. 9. 2009
Prolonged dose-dense epirubicin and cyclophosphamide followed by paclitaxel in breast cancer is feasible.. 8. 2008
Feasibility of accelerated whole-breast radiation in the treatment of patients with ductal carcinoma in situ of the breast.. 8. 2008
Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-overexpressing metastatic breast cancer.. 7. 2007
Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden.. 7. 2007
Biologic markers in axillary node-negative breast cancer: differential expression in invasive ductal carcinoma versus invasive lobular carcinoma.. 7. 2006
Downregulation of the cyclin-dependent kinase inhibitor p27kip1 might correlate with poor disease-free and overall survival in inflammatory breast cancer.. 7. 2006
A phase I study of cetuximab/paclitaxel in patients with advanced-stage breast cancer.. 7. 2006
Final results of a phase II trial of preoperative TAC (docetaxel/doxorubicin/cyclophosphamide) in stage III breast cancer.. 6. 2005
A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane.. 6. 2005
Effect of cardiac dysfunction on treatment outcomes in women receiving trastuzumab for HER2-overexpressing metastatic breast cancer.. 5. 2004
Peripheral neuropathy with microtubule-targeting agents: occurrence and management approach. 2011
Ixabepilone plus capecitabine for breast cancer patients with an early metastatic relapse after adjuvant chemotherapy: two clinical trials. 2010
Levofloxacin-induced radiation recall dermatitis: a case report and a review of the literature. 2010
Adjuvant taxanes: more to the story. 2010
Algorithms for the treatment of patients with metastatic breast cancer and prior exposure to taxanes and anthracyclines. 2010
Evolving approaches to metastatic breast cancer previously treated with anthracyclines and taxanes. 2009
Integrating epothilones into the treatment of patients with metastatic breast cancer: clinical perspectives on incorporating recent data in the practice setting. 2008
Beyond cytotoxic chemotherapy for the first-line treatment of HER2-negative, hormone-insensitive metastatic breast cancer: current status and future opportunities. 2008
Pharmacodynamics of tubulin and tubulin-binding agents: extending their potential beyond taxanes. 2008
New strategies for the treatment of metastatic bone disease. 2007
Ixabepilone, first in a new class of antineoplastic agents: the natural epothilones and their analogues. 2007
Adjuvant taxanes in the treatment of breast cancer: no longer at the tip of the iceberg. 2006
Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M. D. Anderson Cancer Center experience. 2004
Novel approaches to postoperative radiation therapy as part of breast-conserving therapy for early-stage breast cancer. 2003
Breast cancer chemotherapy-related cognitive dysfunction. 2002
Ductal lavage and ductoscopy: the opportunities and the limitations. 2002
New horizons in treating metastatic disease. 2001

VIVO Weill Cornell Medical College

Clinical breast cancer Journal

Overview

publication venue for

Identity

ISO Abbreviation

Linking ISSN

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)